Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

Trial Profile

An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexpramipexole (Primary)
  • Indications Hypereosinophilic syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 09 Jul 2019 According to an Knopp Biosciences media release, an overview data of the eosinophil-lowering effects of dexpramipexole observed in this study will be presented at the 11th Biennial Symposium of the International Eosinophil Society.
    • 24 Apr 2019 According to a Knopp Biosciences media release, results of this study have been presented to the American Society of Hematology.
    • 08 Aug 2018 According to a Knopp Biosciences media release, results from this and other phase 2 trials were summarized on the cover of the August 2, 2018, edition of Blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top